Medtronic PLC Earnings - Q4 2026 Analysis & Highlights
Medtronic delivered strong fiscal 2026 results with accelerating growth across key platforms including Cardiac Ablation Solutions, Symplicity renal denervation, and Hugo surgical robotics, while executing strategic portfolio focus through the MiniMed IPO and targeted M&A investments to drive innovation-led growth into fiscal 2027.
Key Financial Results
Q4 2026 revenue of $9.8 billion, up 9.9% reported and 6.6% organically, representing a 60 basis point acceleration from the prior quarter.
Full fiscal year 2026 revenue of $36.4 billion, up 8.4% reported and 5.8% organically, marking the strongest top line performance in 10 years.
Q4 2026 adjusted EPS of $1.55 and full-year adjusted EPS of $5.53, both ahead of expectations.
Adjusted gross margin of 65.4%, up 30 basis points year-over-year and 50 basis points sequentially.
Adjusted operating margin of 25.5%, including 160 basis points impact from MiniMed Blackstone payment and 80 basis points from tariffs.
Free cash flow of $5.4 billion in fiscal 2026, the strongest since 2022 and ahead of expectations.
Cash and investments of $9.2 billion at year-end, positioning the company favorably for M&A opportunities.
Business Segment Results
Cardiovascular delivered 10% revenue growth, led by 14% in the US and 7% in international markets.
Cardiac Ablation Solutions (CAS) grew 78% worldwide with 124% growth in the US, now annualizing over $2 billion in revenue and on track to reach $2 billion trailing in Q1 fiscal 2027.
Pulmonary Vein Ablation (PFA) saw exceptional global growth of 145%, with Sphere-9 demonstrating broad versatility.
Cardiac Rhythm Management delivered 5% growth in both US and international markets, with mid-teens growth in Micra and high-teens in SelectSecure 3830 lead.
Defibrillation delivered mid-single digit growth, including high-teens in ICD and mid-60s in EV-ICD.
Structural Heart performance was flat, with strong international performance offset by softer US performance due to low-risk data, though weekly US procedure volumes have stabilized over the last eight weeks.
Symplicity renal denervation annualizing at $100 million, with doubled average weekly procedure volumes since the National Coverage Determination (NCD).
Neuroscience delivered 3% revenue growth globally, driven by 6% in international markets.
Cranial & Spinal Technologies (CST) was up 3% in both US and international markets, with Core Spine growing 6% on ModuleX expansion.
Stealth AXiS navigation platform achieved FDA clearance across Spine, Cranial, and ENT indications with CE Mark for Spine and Cranial, with sales off to a very strong start.
Neurovascular was up 6%, driven by 11% growth in Hemorrhagic, including adoption of Neuroguard and Artisse.
Specialty Therapies delivered 3% growth, with Neuromodulation up low-single digit.
Pelvic Health results were flat as solid growth in Altaviva was offset by broader market softness in sacral nerve modulation.
Medical Surgical delivered 5% growth globally, including 8% in the US.
Surgical revenue increased 3% globally, split evenly between US and international markets, driven by high-single digit growth in Advanced Energy and Wound Management plus increased Hugo contribution.
Endoscopy delivered high-single digit growth, driven by strong adoption of Endoflip and market share gains in Nexpowder.
Acute Care and Monitoring was up 11%, including high-teens growth in the US, driven by mid-teens growth in Nellcor pulse oximetry.
Diabetes business delivered 15% reported growth or 8.1% organic, driven by strong international execution and continued momentum in US CGM.
Capital Allocation
Completed MiniMed IPO in early March, establishing it as a standalone publicly traded company.
Closed CathWorks transaction in Coronary portfolio, acquiring FFRangio System using AI and advanced computational science.
Announced plans to acquire Scientia and SPR Therapeutics, expanding neurovascular platform with guidewire technologies and chronic pain management therapies.
Made investments in Beluga Medical and CardioACC to advance next-generation ICE catheters for EP toolkit.
Invested in Pulnovo, a first-of-its-kind minimally invasive system for pulmonary artery denervation.
Entered distribution agreement with Merit Medical for ViaVerte, an FDA-cleared solution for chronic vertebrogenic back pain.
Closed or announced nearly $2 billion of additional investments in Q4 through M&A and venture capital strategy.
Made 16 venture investments totaling approximately $250 million in fiscal year 2026.
Expected recent M&A to contribute approximately $150 million to inorganic revenue growth in fiscal 2027.
R&D grew $150 million as the company marches towards higher investment goals.
CapEx spend was up roughly $50 million and grew at a significantly lower rate than revenue.
Industry Trends and Dynamics
CAS market grew approximately 20% in Q4, with mid- to high-teens market growth expected in fiscal 2027.
Medtronic growing north of two times the CAS market rate, with approximately 15% share and marching towards market leadership.
$14 billion CAS market with strong growth trajectory.
Hypertension represents a massive unmet need, with roughly 18 million people living with uncontrolled hypertension in the US alone despite multiple medications.
Neuromodulation space growing over 20% annually.
FFRangio targeting $1 billion segment growing in the low-double digits for coronary interventions.
Hugo worldwide procedure volume growth is 2x to 3x the market, with utilization increasing.
Competitive Landscape
Medtronic has the most comprehensive Neuroscience portfolio and is the number one player and category leader across each segment.
Medtronic is the proven platform in renal denervation category with enormous unmet need, standing apart with robust and growing clinical evidence, broad label, expanding reimbursement, and growing demand.
Sphere-360 is the only rotation-free, large tip, single-shot catheter available, launching in Europe with strong physician feedback.
Cardiac Rhythm Management sees opportunity where other companies see a mature market, innovating and driving market growth.
Medtronic gaining an additional 8 points of US share in CAS.
Macroeconomic Environment
Tariffs impacted the business by $74 million or 80 basis points in Q4, in line with expectations.
Anticipated tariff impact to COGS of approximately $250 million in total for fiscal 2027, including $75 million in the first quarter.
Roughly 1 point headwind from increased fuel and transportation costs due to conflict in the Middle East embedded in guidance.
Foreign exchange expected to be neutral to roughly $100 million headwind for full year fiscal 2027, with approximate neutral to $50 million tailwind to the first quarter.
MedTech is structurally resilient because fundamentals are durable, with people living longer and chronic disease rising.
China remains a growth market with VBP (Volume-Based Procurement) headwinds behind the company, though profitability remains strong and the business is accretive.
Growth Opportunities and Strategies
Expanding entire EP ecosystem geographically into new indications with exciting cadence of new innovation.
Launched Sphere-9 in Japan where market leadership is expected to extend.
Secured FDA approval for US VT pivotal trial aiming to begin enrollment in first half of fiscal 2027.
Continuing to invest in fully integrated EP ecosystem with two targeted investments in ICE catheter technology for real-time heart visualization.
Symplicity physician finder spans 200 doctors across more than 300 accounts, connecting patients with physicians as demand grows.
Presented late-breaking long-term data on Symplicity showing sustained mean systolic blood pressure reductions of 13.3 and 18.1 mmHg at three years with 90% of patients achieving meaningful benefit.
Hugo launched for urology in the United States, placing systems at leading institutions and treating first patients with positive feedback.
Submitted to FDA for 510(k) clearance for general surgery and gynecologic indications plus LigaSure RAS vessel sealer.
Received FDA clearance for ProGrip advanced mesh optimized for robotic-assisted ventral hernia repair.
Touch Surgery digital ecosystem has over 1,400 installations, up 30% plus sequentially.
Altaviva trained nearly 1,000 physicians since launch with active implanters up three times sequentially and patients treated up two and a half times.
Prism-2 next-generation mapping software launched globally, unlocking improved navigation using hybrid impedance and magnetic mapping.
Stealth AXiS is a force multiplier driving pull-through across planning, robotics, and broader AiBLE ecosystem with robotics penetration still in high-single digits.
Scientia acquisition represents significant advancement in navigation, enabling neuro interventionalists to reach areas of the brain historically difficult to access.
SPR Therapeutics acquisition will build out portfolio of chronic pain management therapies.
Financial Guidance and Outlook
Fiscal 2027 organic revenue growth guidance of 6.75% to 7.25%, including approximately 11.5% to 12% organic growth in the first quarter.
Guidance includes roughly 25 basis points tailwind from Diabetes business.
Additional selling week expected to contribute approximately 125 basis points to full-year growth and 500 basis points to 600 basis points in the first quarter.
Fiscal 2027 margin expected to be roughly in line with previous year, excluding tariffs, with pricing and COGS efficiency programs offsetting business mix impact.
Fiscal 2027 gross margin expected to decrease by roughly 20 basis points including tariffs.
Fiscal 2027 operating margin expected to be up 60 basis points, driven by absence of Blackstone milestone payments and operating leverage.
Approximate 200 basis points headwind below operating profit line, driven by increase in net interest expense and slightly higher tax rate.
Fiscal 2027 EPS guidance of $5.90 to $6.00.
First quarter fiscal 2027 EPS guidance of $1.38 to $1.40, including 600 basis points to 700 basis points benefit from extra selling week.
2% dilution from M&A factored into guidance, roughly 1 point higher than prior quarter due to earlier-than-anticipated deal timing.
Full tariff impact of $250 million taken into consideration, an increase of $65 million versus prior year.
Foreign exchange expected to have neutral to 1% accretive impact for full year based on recent FX rates.
Conservative approach taken on MiniMed separation, including full year of Diabetes business in estimates with no separation share count benefit assumed in fiscal 2027.
Potential upside from current guidance should MiniMed separate prior to year-end as intended.
Leadership and Organizational Changes
Brett Wall leaving Medtronic after 25-year career, having played defining role in shaping Neuroscience portfolio and establishing interventional stroke as global standard of care.
Dr. Kweli Thompson stepping into role of Executive Vice President and President of Neuroscience portfolio, a proven leader with strong track record from leading CRM business.
